40 results about "Genus Shigella" patented technology

The invention discloses a novel method for identifying Shigella sonnei by using MALDI-TOF-MS. The invention provides an identification method for distinguishing whether a to-be-detected strain is Shigella sonnei or other batacteria. The invention also discloses application of a set consisting of a MALDI-TOF-MS detection instrument, a reagent for the MALDI-TOF-MS detection instrument and a readable carrier. The readable carrier can record the following conditions: if protein peaks obtained after detection of the to-be-detected strain by using MALDI-TOF-MS contains the four characteristic protein peaks with mass-charge ratios of 5612.81 + / - 8.7, 4871.12 + / - 45.9, 4164.03 + / - 26 and 3247.05 + / - 6.9, respectively, the to-be-detected strain is Shigella sonnei or candidate Shigella sonnei. Experimental results prove that MALDI-TOF-MS has good accuracy and specificity in identification of Shigella sonnei and shortens identification time.

The invention relates to a method for synchronously separating and identifying salmonella and shigella in enteric pathogenic bacteria, which mainly solves the technical problems of high detection-missing rate, complicated identification step, high cost and unintuitive screening result in the existing method for separating the salmonella and the shigella. The kit comprises: 1) a TSB (Trypticase Soy Broth) serving as an universal-type non-selective proliferous liquid; 2) a 10-folds concentrated TSB serving as a 10-folds concentrated universal-type non-selective proliferous liquid; 3) a selenite brilliant green-sulfanilamide proliferous liquid serving as a salmonella proliferous liquid; 4) a shigella proliferous liquid; 5) a xylose lysine deoxycholate agar plate; 6) a salmonella chromogenic agar plate; 7) a salmonella-shigella comprehensive biochemical identification tube comprising a first test tube and a second test tube; 8) a hydrogen sulphide filter paper strip; and 9) an indole filter paper strip. In the invention, typical colonial morphology corresponding to the growth of a selective isolation medium, simple biochemistry and reaction combination test of a specific enzyme and a substrate are adopted to identify two kinds of enteric pathogenic bacteria.

The invention discloses an anti-I type Shiga toxin IgY antibody, and the antibody can be prepared by the following method: non-toxic Shiga toxin immune antigen is prepared by the method of chemical synthesis or gene recombinant expression, egg-laying hens are immunized, eggs are collected, and the biological chemical method is applied in extracting and purifying egg yolk immunoglobulin (IgY antibody). The antibody has the effects of neutralizing Shiga toxin and effectively inhibiting the toxicity of the Shiga toxin, can be used as an oral antitoxin for preventing and treating complications caused by toxin-producing Shigella, entero-hemorrhagic Escherichia coli O157, vibrio cholerae and the like and can be simultaneously applied in the detection and the infection diagnosis of type I Shiga toxin and pathogen thereof.

The invention relates to a Shigella flexneri serotype detection primer, and multiplex amplification using it. The primer comprises sequences represented by SEQ ID Nos.2 and 3, SEQ ID Nos.4 and 5, SEQ ID Nos.6 and 7, SEQ ID Nos.8 and 9, SEQ ID Nos.10 and 11, SEQ ID Nos.12 and 13, SEQ ID Nos.14 and 15, SEQ ID Nos.16 and 17, SEQ ID Nos.18 and 19. The primer is specific and has an annealing temperature consistency. The invention also relates to a method for realizing the multiplex amplification by using the primer, and further relates to an application of the Shigella flexneri serotype detection primer in the preparation of a detection agent, and a Shigella flexneri serotype detection kit including the primer.

The invention discloses a nontoxic shigella flexneri with lipopolysaccharide synthesis deficiency and a construction method thereof. The invention provides a recombinant bacterium A, which is a recombinant bacterium obtained by removing large virulence plasmid in shigella flexneri 2a and O-antigen ligase coding gene in genome of the shigella flexneri 2a. Experiments show that according to the method of the invention, large virulence plasmid in shigella flexneri 2a 301 is firstly removed based on a plasmid exclusion principle, and a large virulence plasmid traceless deletion mutant 301 delta pCP is constructed, which is the nontoxic shigella flexneri; a target gene is substituted by a resistance gene by using homologous recombination technology based on the action of lambda bacteriophage Red recombinase; then the resistance gene is removed from a host bacterium under the action of transposase, and thus a waaI deletion strain of the nontoxic shigella flexneri is obtained.

With the goal of creating a combination vaccine against Shigella and other diarrheal pathogens we have constructed a prototype vaccine strain of Shigella flexneri 2a (SC608) that can serve as a vector for the expression and delivery of heterologous antigens to the mucosal immune system. SC608 is an asd derivative of SC602, a well-characterized vaccine strain, which has recently undergone several phase 1 and 2 trials for safety and immunogenicity. Using non-antibiotic asd-based plasmids, we have created novel constructs for the expression of antigens from enterotoxigenic E. coli (ETEC), including CFA / I (CfaB and CfaE) and the B-subunit from heat-labile enterotoxin (LTB) in Shigella vaccine strain SC608. Heterologous protein expression levels and cellular localization are critical to immune recognition and have been verified by immunoblot analysis. Following intranasal immunization (SC608(CFAI) and SC608(CFAI / LTB) of guinea pigs, serum IgG and IgA immune responses to both the Shigella LPS and ETEC antigens can be detected by ELISA. In addition, ELISPOT analysis for ASCs from cervical lymph nodes and spleen showed similar responses. All vaccine strains conferred high levels of protection against challenge with wild-type S. flexneri 2a using the Sereny test. Furthermore, serum from guinea pigs immunized with SC608 expressing CfaB and LTB contained antibodies capable of neutralizing the cytological affects of heat-labile toxin (HLT) on Chinese Hamster Ovary (CHO) cells. These initial experiments demonstrate the validity of a multivalent invasive Shigella strain that can serve as a vector for the delivery of pathogen-derived antigens.

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype la, lb, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

The application provides a method for detecting bacterium serotypes. Through the adoption of the method, the existence of various bacterium serotypes (such as escherichia coli O serotypes, escherichiacoli H serotypes, escherichia coli K serotypes, salmonella O serotypes, salmonella H serotypes, vibrio parahaemolyticus O serotypes, vibrio parahaemolyticus K serotypes, shigella O serotypes and vibrio cholerae O serotypes) in samples can be detected at the same time. In addition, the application further provides a probe set and a reagent kit comprising one or more probe sets. The probe sets andthe reagent kit can be used for implementing the method disclosed by the invention. In addition, the application further provides the reagent kit. The existence or the level of a plurality of bacterium serotypes in the samples can be detected at the same time in a round of reactions.

The invention relates to the field of biological detection, and particularly relates to a substrate combination, a detection reagent and a detection kit for detecting escherichia coli and / or shigella.The substrate combination provided by the invention is a detection kit for quickly distinguishing escherichia coli and the shigella based on biochemical and chromogenic principles and a preparation method thereof is provided. By using the kit disclosed by the invention, the escherichia coli, shigella bogdii, shigella sonnei, shigella flexneri and shigella dysenteriae can be quickly distinguishedwithin 1-2 hours by only one step of operation.

The invention relates to a detection reagent for a Shigella flexneri plasmid-carried gene Ipt-O and an application thereof, and in particular relates to an application of the detection reagent for a Shigella flexneri plasmid-carried gene Ipt-O in preparation of a Shigella flexneri serotype detection agent. The detection agent is used for detecting the Shigella flexneri serotype or detecting the differential diagnosis sample containing Shigella flexneri. The invention also relates to a reagent for Shigella flexneri MASF IV-1 phenotype detection, which is composed of a primer pair of the Shigella flexneri plasmid-carried gene Ipt-O as shown in the SEQ ID No.2 and SEQ ID No.3, and further relates to a method for detecting the Shigella flexneri MASF IV-1 phenotype by using the primer pair, and a method for distinguishing Shigella flexneri Xv serotype and X serotype, 4a serotype and 4av serotype as well as Y serotype and Yv serotype.

The invention belongs to the technical field of medicinal chemistry, and discloses an emodin azole alcohol compound as shown in formula I, which has strong antimicrobial activity in vitro, especially against Staphylococcus aureus, Bacillus subtilis and Micrococcus luteus , Escherichia coli, Proteus, Pseudomonas aeruginosa, Shigella dysenteriae, Salmonella typhimurium and other bacteria, as well as Candida utilis, Candida albicans, Saccharomyces cerevisiae, Aspergillus flavus, Candida, etc. Fungi show high inhibitory activity and can be used to prepare antibacterial and / or antifungal drugs, thereby providing more efficient drug candidates for clinical antimicrobial treatment, and helping to solve the increasingly serious drug resistance, stubborn Clinical treatment issues such as pathogenic microorganisms and emerging harmful microorganisms.

The invention discloses the application of Prunus japonica extract in the preparation of antibacterial products. Plum extract has a significant inhibitory effect on Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Shigella flexneri, Proteus, Salmonella typhi, Pseudomonas aeruginosa, and Escherichia coli, and will be used as an antibacterial agent in the future. There is significant potential in research for the development of drugs and other antimicrobial products.

The invention discloses escherichia coli and shigella detection primers based on a specific sequence, a kit and a detection method, belonging to the technical field of molecular biology. The primers are designed and synthesized for a specific sequence (as shown in SEQ ID NO. 3) shared by escherichia coli and shigella or a homologous sequence, the homology of which reaches 96% or above. The primers are specifically as shown in SEQ ID NO.1 and SEQ ID NO.2. The detection method comprises the steps of by taking genomic DNA of a to-be-detected sample or a single colony as a template, performing PCR amplification by means of the primers; judging the amplification primers as suspected positive if the amplification primers have same stripes with positive control; recovering the amplification primers which are suspected positive; performing sequencing and analyzing; and judging the primers which are as same as the sequence as shown in the SEQ ID NO.3 or the homology of which reaches 96% or above, as escherichia coli and shigella positive. According to the detection method, the operation is high, sensitivity and specificity are high, the result is consistent to species results of escherichia coli and shigella, the detection cost is low and the method has good promotion and application prospect.

The invention belongs to the technical field of medicinal chemistry. The invention discloses an emodin azole alcohol compound as shown in a formula I which is described in the specification. The compound has relatively strong in-vitro antimicrobial activity; the compound has very high inhibitory activity on staphylococcus aureus, bacillus subtilis, micrococcus luteus, escherichia coli, proteus, pseudomonas aeruginosa, shigella dysenteriae, salmonella typhimurium and other bacteria, and candida utilis, candida albicans, saccharomyces cerevisiae, aspergillus flavus, candida albicans and other fungi. The compound can be used for preparing antibacterial and / or antifungal drugs, so that more efficient candidate drugs are provided for clinical antimicrobial treatment, and the clinical treatmentproblems of increasingly serious drug resistance, stubborn pathogenic microorganisms, newly appearing harmful microorganisms and the like are solved.

The present invention provides a LAMP primer and a detection method for detecting Shigella flexneri 2a and Xv serotypes. The present invention designs LAMP primers according to the type-specific antigenic determinants and group-specific antigenic determinants of the main serotypes 2a and Xv of Shigella flexneri, wherein the 2a serotype is (gtrII and wzx genes are positive, gtrX and opt genes are negative) ), Xv serotype (gtrX, opt and wzx genes positive, gtrII gene negative). The method does not require expensive equipment and instruments, and can rapidly, accurately and specifically detect Shigella flexneri 2a and Xv serotypes.

The invention discloses a making method of short peptide to inhibit shigellosis with amino acid as list 1, which is characterized by the following: adding chemical group, amino acid, peptide, protein, PEG, marked material to N and C ends to do kinds of chemical or biological decoration; optimizing the stability or other applying property and using scale; fitting for treat shigellosis, enterorrhagia escherichia coli O157 and cholera vibrio.

A method, comprising the steps of providing a sample containing contaminating nucleoside diphosphates and / or nucleoside triphosphates, such as ATP and / or ATP analogues including deoxyribonucleoside triphosphates;reducing the amount of the contaminating nucleoside diphosphates and / or nucleoside triphosphates in the sample with an apyrase enzyme, wherein said apyrase enzyme is a Shigella flexneriapyrase; andperforming an analysis of the sample, wherein said analysis comprises an assay that would have been affected by the contaminating nucleoside diphosphates and / or nucleoside triphosphates had they not been reduced in the reduction step.